Publications
1. ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial. Nature npj Precision. Oncology. 9, 86 (2025).
PDF : https://doi.org/10.1038/s41698-025-00874-0
2. A New and Effective Procedure for Advanced Oral Cancer Therapy: The Potential of a Cancer Stem Cell Assay in Guiding Chemotherapy. Transl Med UniSa. 2023 Dec 8;25(1):16-27. doi: 10.37825/2239-9747.1042. PMID: 38143509
3) Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial. Cell Reports Medicine 2023 May 16;4(5):101025. doi: 10.1016/j.xcrm.2023.101025. Epub 2023 May 2. PMID: 37137304
4) Treatment of unmethylated MGMT promoter recurrent glioblastoma with cancer stem cell assay-guided chemotherapy and the impact on patients’ healthcare costs. Neurooncol Adv. 2023 May 12;5(1):vdad055. doi: 10.1093/noajnl/vdad055. eCollection 2023 Jan-Dec. PMID: 37287692
5) Multi-institutional randomized phase-3 trial comparing cancer stem cell-targeted vs physician-choice treatments in patients with recurrent high-grade glioma (NCT03632135). Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, LA, April 8-12, 2022.
6) Multi-institutional randomized phase-3 trial comparing cancer stem cell-targeted vs physician-choice treatments in patients with recurrent high-grade glioma (NCT03632135). Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago, IL, June 3-7, 2022.
7) Cancer Stem Cell Assay for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer. Stem Cell Res Dev Ther 2021, 7: 076 DOI: 10.24966/SRDT-2060/100076
8) Initial Analysis of Phase-III Trial – Standard Chemotherapy vs. Chemotherapy Guided by a Cancer Stem Cell Test in Recurrent Glioblastoma (NCT03632135). Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii50, https://doi.org/10.1093/neuonc/noaa215.20
9) Clinical Relevance of Cancer Stem Cell Cytotoxicity Assay in Guiding Treatment of Glioblastoma. Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii200, https://doi.org/10.1093/neuonc/noaa215.838
10) Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancer. Transl Oncol. 2020; 13;(12):100860. doi: 10.1016/j.tranon.2020.100860
11) Cancer Stem Cell Chemotherapeutics Assay for Prospective Treatment of Recurrent Glioblastoma and Progressive Anaplastic Glioma: A Single-Institution Case Series. Transl Oncol. 2020 Mar 17;13(4):100755. doi: 10.1016/j.tranon.2020.100755
12) Prospective analysis of cancer stem cells drug response assay for glioblastoma patients. 2018 Neuro-Oncology, Vol 20, Issue suppl_6, 5 November 2018, Pages vi243
13) Prospective analysis of cancer stem cells drug response assay for glioblastoma patients. 2018 ASCO Annual Meeting. J Clin Oncol 36, 2018 (suppl; abstr 2057)
14) Efficacy of ChemoID guided drug selection for palliative chemotherapy in advanced recurrent high-grade ovarian adenocarcinoma: case study. Translational Medicine Reports, (2017) 1: 6701, 70-75.
15) The future of precision medicine in oncology: targeting cancer stem cells. Editorial | Clinics in Oncology, (2017) 2: 1187, 1-3.
16) Analysis of Chemopredictive Assay for Targeting Cancer Stem Cells in Glioblastoma Patients. Research Article | Translational Oncology, (2017) 10, 241-254.
17) Functional drug response assay for cancer stem cells in the era of precision medicine. Editorial | Translational Medicine Reports, (2017) 1: 6421, 7-10.
18) Analysis of chemo-predictive assay for targeting cancer stem cells in 41 glioblastoma patients. 2017 ASCO Annual Meeting. J Clin Oncol 35, 2017 (suppl; abstr e13544)
19) A new complementary procedure for patients affected by head and neck cancer: Chemo-predictive assay. Research Article | International Journal of Surgery Case Reports, 26 (2016) 42-46.
20) ChemoID assay for glioblastoma. 2015 ASCO Annual Meeting. J Clin Oncol 33, 2015 (suppl; abstr e13028)
21) Chemo-Predictive Assay for Targeting Cancer Stem-Like Cells in Patients Affected by Brain Tumors. Research Article | published 21 Aug 2014 | PLOS ONE10.1371/journal.pone.0105710
22) Novel chemosensitivity assay for targeting cancer stem-like cells in brain tumors. 2014 ASCO Annual Meeting. J Clin Oncol 32, 2014 (suppl; abstr e13012)
23) ChemoID assay for patients with primary brain tumors. 2013 ASCO Annual Meeting. J Clin Oncol 31, 2013 (suppl; abstr 2089)
24) ChemoID assay for anaplastic spinal ependymoma. 2013 ASCO Annual Meeting. J Clin Oncol 31, 2013 (suppl; abstr e13040)
25) Rapid Selection and Proliferation of CD133(+) Cells from Cancer Cell Lines: Chemotherapeutic Implications. Research Article | published 08 Apr 2010 | PLOS ONE10.1371/journal.pone.00100351)
Skip to content